Cancer of the Prostate

  • W. G. Jones
  • P. H. Smith
Part of the UICC International Union Against Cancer book series (UICCI)

Abstract

Prostatic cancer is predominantly found in elderly males and is becoming increasingly important as life expectancy rises. It is now the second or third most common malignant disease in men in Western countries with one in ten men developing clinical evidence of the disease. However, only a third of diagnosed patients die of the condition, for mortality is usually from other causes in the elderly patient. Approximately half of patients present at a time when the cancer is clinically localized; the other half already have metastatic disease at initial diagnosis. Metastases are commonly to bone, where the lesions can be seen on X-rays as (almost exclusively) osteosclerotic lesions (Fig. 1) or on a bone scan as areas of increased activity known as “hot spots” (Fig. 2). Treatment for patients with metastatic disease is usually hormonal and is thus palliative rather than curative.

Keywords

Filtration Europe Lymphoma Estrogen Adenocarcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  1. Denis L (1991) Controversies in the management of localised and metastatic prostatic cancer. European Journal of Cancer 27: 333–341PubMedCrossRefGoogle Scholar
  2. Fleming C, Wasson JH, Albertsen PC et al. (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Journal of the American Medical Association 269: 2650–2658PubMedCrossRefGoogle Scholar
  3. Furr BJA, Denis L (eds) (1988) Bailliere’s clinical oncology. International practice and research, vol 2, no 3. Prostatic cancer. Bailliere Tindall, LondonGoogle Scholar
  4. Gittes RF (1991) Carcinoma of the prostate. New England Journal of Medicine 324: 236–245PubMedCrossRefGoogle Scholar
  5. Hanks GE (1988) Radical prostatectomy or radiation therapy for early prostate cancer: two roads to the same end. Cancer 61: 2153–2160PubMedCrossRefGoogle Scholar
  6. Jones WG (1991) The role of chemotherapy in refractory prostate cancer. Current Opinion in Urology 1: 21–24CrossRefGoogle Scholar
  7. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK (1993) Prostate cancer screening: what we know and what we need to know. Annals of Internal Medicine 119: 914–923PubMedCrossRefGoogle Scholar
  8. Pienta KJ, Esper PS (1993) Risk factors for prostate cancer. Annals of Internal Medicine 118: 793–818PubMedCrossRefGoogle Scholar
  9. Pienta KJ, Esper PS (1993) Is dietary fat a risk factor for prostate cancer? Journal of the National Cancer Institute 85: 1538–1540PubMedCrossRefGoogle Scholar
  10. Walsh PC (1987) The role of radical prostatectomy in the management of prostatic cancer. Cancer 60: 526–537PubMedCrossRefGoogle Scholar
  11. Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE, Sherman NE (1991) The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 68: 2370–2377PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • W. G. Jones
  • P. H. Smith

There are no affiliations available

Personalised recommendations